DCT

1:26-cv-05142

Salix Pharma Ltd v. Hetero Labs Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-05142, D.N.J., 05/07/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey based on Defendant Hetero USA, Inc. having its principal place of business in the district, conducting business there, and having assisted in the preparation and submission of the at-issue Abbreviated New Drug Application (ANDA) from New Jersey. Venue for the foreign defendants is based on their being subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an ANDA to the FDA seeking approval to market a generic version of Xifaxan® (rifaximin) 550 mg tablets constitutes an act of infringement of three U.S. patents related to methods of treating Irritable Bowel Syndrome (IBS) and polymorphic forms of rifaximin.
  • Technical Context: The dispute is in the pharmaceutical sector, concerning a low-absorption antibiotic, rifaximin, used to treat gastrointestinal disorders, and specific dosing regimens and crystalline forms of the active pharmaceutical ingredient.
  • Key Procedural History: This is a patent infringement action filed under the Hatch-Waxman Act. The suit was triggered by a Notice Letter dated March 27, 2026, in which Defendants informed Plaintiffs of their filing of ANDA No. 220749 containing a Paragraph IV certification, asserting that Plaintiffs' patents are invalid, unenforceable, and/or will not be infringed by the proposed generic product.

Case Timeline

Date Event
2005-03-03 '196 Patent Priority Date
2008-02-26 '571 Patent Priority Date
2008-02-26 '912 Patent Priority Date
2012-06-05 '196 Patent Issue Date
2023-01-31 '912 Patent Issue Date
2023-10-10 '571 Patent Issue Date
2026-03-27 Defendants' ANDA Notice Letter to Plaintiffs
2026-05-07 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,779,571 - "Methods for Treating Irritable Bowel Syndrome (IBS)", issued October 10, 2023

The Invention Explained

  • Problem Addressed: The patent family addresses the need for effective treatments for Irritable Bowel Syndrome (IBS), a chronic gastrointestinal disorder compl. ¶32 Rifaximin was known as a gastrointestinal antibiotic, but specific, effective, and durable treatment regimens for IBS were sought '912 Patent, col. 1:26-54
  • The Patented Solution: The invention provides a specific method of treating symptoms associated with diarrhea-predominant IBS (dIBS), particularly in female patients, by administering a defined dosage regimen of rifaximin (550 mg, three times a day for 14 days) '571 Patent, claim 1 The specification explains that this short course of treatment was discovered to provide a "durability of response," meaning symptoms remained relieved for a significant period even after the antibiotic was discontinued '912 Patent, col. 2:56-4:6
  • Technical Importance: This approach provided a short-course antibiotic therapy for a chronic condition, offering sustained symptom relief without requiring continuous, long-term medication, which represented a significant shift in managing IBS '912 Patent, col. 14:33-50

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '571 Patent without specifying which claims are asserted Compl. ¶46
  • Independent claim 1 recites the following essential elements:
    • A method of treating bloating associated with diarrhea-predominant irritable bowel syndrome (dIBS) in a female subject,
    • said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject,
    • thereby treating bloating associated with dIBS in the female subject.

U.S. Patent No. 11,564,912 - "Methods for Treating Irritable Bowel Syndrome (IBS)", issued January 31, 2023

The Invention Explained

  • Problem Addressed: As with the related '571 Patent, the invention addresses the need for an effective treatment for the symptoms of IBS '912 Patent, col. 1:41-54
  • The Patented Solution: The patent discloses methods of treating IBS by administering a specific regimen of rifaximin (550 mg, three times a day for 14 days), which provides a durable response and lasting symptom relief even after the two-week treatment course concludes '912 Patent, abstract '912 Patent, col. 2:56-4:6 The specification presents clinical trial data demonstrating this durable efficacy '912 Patent, figs. 1-2
  • Technical Importance: The invention established a novel therapeutic paradigm for IBS, using a short course of a non-systemic antibiotic to achieve long-term remission of symptoms for what is typically a chronic, relapsing condition '912 Patent, col. 14:33-50

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '912 Patent without specifying which claims are asserted Compl. ¶58
  • Independent claim 1 recites the following essential elements:
    • A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a female subject,
    • said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject,
    • thereby treating one or more symptoms of IBS in the female subject.

Multi-Patent Capsule

  • Patent Identification: U.S. Patent No. 8,193,196, "Polymorphous Forms of Rifaximin, Processes for their Production and Use thereof in the Medicinal Preparations", issued June 5, 2012 Compl. ¶34
  • Technology Synopsis: The patent addresses the problem that active pharmaceutical ingredients can exist in different crystalline structures (polymorphs) with different properties '196 Patent, col. 1:51-64 The invention provides specific polymorphous forms of rifaximin, designated as forms δ and ε, and processes to produce them, noting that these forms have different systemic absorption profiles, which can be leveraged for different therapeutic effects '196 Patent, abstract '196 Patent, col. 3:1-9
  • Asserted Claims: The complaint generally asserts infringement of "one or more claims" of the '196 Patent Compl. ¶70
  • Accused Features: The complaint alleges that the manufacture and sale of Defendants' ANDA Product will infringe claims to a composition comprising a polymorphic form of rifaximin Compl. ¶69 Compl. ¶70

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendants' generic rifaximin 550 mg tablets, identified as the "ANDA Product" associated with ANDA No. 220749 Compl. ¶2
  • Functionality and Market Context: The ANDA Product is a generic version of Plaintiffs' Xifaxan® 550 mg tablets and seeks FDA approval for the same indication: the treatment of IBS-D in adults Compl. ¶31 Compl. ¶38 The submission of the ANDA itself is the statutorily defined act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶44 Compl. ¶56 Compl. ¶68 The complaint alleges that, if approved, the ANDA Product would be a direct market competitor to Xifaxan® Compl. ¶11

IV. Analysis of Infringement Allegations

The complaint does not contain a detailed claim chart. The infringement allegations are based on the future, intended use of the ANDA product as will be directed by its labeling upon approval.

'571 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating bloating associated with diarrhea-predominant irritable bowel syndrome (dIBS) in a female subject, The ANDA Product seeks approval for the treatment of IBS-D in adults, and the complaint alleges it will be prescribed to and administered to human patients, including females, to relieve dIBS symptoms. ¶38; ¶47 col. 4:34-36
said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject, The ANDA Product is a 550 mg rifaximin tablet, and the complaint alleges its proposed labeling will instruct a dosing regimen that infringes the claimed method. ¶37; ¶47 col. 6:45-50
thereby treating bloating associated with dIBS in the female subject. The alleged use of the ANDA Product as instructed by its label would result in the treatment of bloating associated with dIBS. ¶47 col. 2:56-65

'912 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating one or more symptoms of irritable bowel syndrome (IBS) in a female subject, The ANDA Product is intended for the treatment of IBS-D, and the complaint alleges it will be prescribed to female patients to relieve the signs and symptoms of IBS. ¶38; ¶59 col. 4:34-36
said method comprising administering, 550 mg of rifaximin TID for 14 days to the female subject, The ANDA Product is a 550 mg rifaximin tablet, and the complaint alleges its proposed labeling will instruct a dosing regimen that infringes the claimed method. ¶37; ¶59 col. 6:45-50
thereby treating one or more symptoms of IBS in the female subject. The alleged use of the ANDA Product as instructed by its label would result in the treatment of IBS symptoms. ¶59 col. 2:56-65
  • Identified Points of Contention:
    • Scope Questions: For the '571 and '912 patents, a primary question will be whether the proposed label for the ANDA Product will be construed by the court as specifically encouraging or instructing the administration of the drug to "a female subject" for "14 days" at a "TID" (three times daily) dosage, as required by the claims. The complaint does not detail the specific language of the proposed label.
    • Technical Questions: For the '196 Patent, the central dispute will be a factual one: does the Defendants' ANDA Product contain a polymorphic form of rifaximin that falls within the scope of the asserted claims? The complaint alleges it will, but this will require discovery and expert analysis of the physical product Compl. ¶70

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a deep analysis of claim construction disputes. However, based on the patent language, the following terms may be central.

Term: "treating" (from Claim 1 of the '571 and '912 Patents)

  • Context and Importance: The definition of "treating" is critical because it could determine whether mere temporary symptom relief infringes, or if a more durable, lasting effect is required. Practitioners may focus on this term because the patents' specifications emphasize a "durability of response" that persists after the 14-day treatment period ends.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain and ordinary meaning of "treating" generally includes any action taken to ameliorate a disease or its symptoms. The claim language itself does not explicitly require a durable response.
    • Evidence for a Narrower Interpretation: The specification repeatedly highlights the discovery of a "durability of antibiotic response" and "adequate relief of symptoms after removal of treatment" '912 Patent, col. 2:56-4:6 A defendant could argue that "treating" in the context of this patent requires achieving this specific, durable outcome, not just transient relief during administration.

Term: "a female subject" (from Claim 1 of the '571 and '912 Patents)

  • Context and Importance: This term narrows the claims significantly, limiting the method to a specific patient population. Its construction is important for infringement, especially indirect infringement. Practitioners may focus on this term because if the ANDA label is for "adults" generally, the analysis will turn on whether such a label induces infringement of a claim limited to females.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term itself is unambiguous. Plaintiffs may argue that if a drug is prescribed to a general population that includes females for the claimed indication, and a substantial number of those administrations are to females, that is sufficient for inducement.
    • Evidence for a Narrower Interpretation: Defendants may argue that to "actively induce" infringement, the label must specifically instruct or encourage use in the claimed "female subject" population, and a general "adult" indication is insufficient, potentially raising questions about whether the label can be "carved out" to avoid the patented method.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendants will induce infringement of all three patents-in-suit Compl. ¶¶50-51 Compl. ¶¶62-63 Compl. ¶73 The basis for this allegation is that Defendants' ANDA Product, if approved, would be sold with a label instructing physicians and patients to use the drug in a manner that directly infringes the asserted method claims. Knowledge and intent are alleged to arise from Defendants' awareness of the patents via their listing in the FDA's Orange Book and the Paragraph IV certification letter sent to Plaintiffs Compl. ¶53 Compl. ¶65 Compl. ¶77
  • Willful Infringement: The complaint alleges that Defendants' infringement of all three patents will be willful, intentional, and deliberate Compl. ¶49 Compl. ¶61 Compl. ¶74 This allegation is based on alleged pre-suit knowledge of the patents, as evidenced by the Orange Book listing and the Notice Letter detailing the ANDA filing Compl. ¶53 Compl. ¶65 Compl. ¶77 The complaint further characterizes the case as "exceptional" to support a claim for attorneys' fees Compl. ¶40

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue for the method patents ('571 and '912) will be one of induced infringement: does the proposed label for Defendants' generic product, by seeking an indication for treating IBS-D in adults, actively encourage or instruct the specific patented method of "administering, 550 mg of rifaximin TID for 14 days" to "a female subject," or will Defendants argue their label does not map onto the claims?
  • A second key question will be one of validity: as signaled by the Defendants' Paragraph IV certification, the litigation will likely center on whether the asserted claims of the patents-in-suit are valid over the prior art, particularly focusing on obviousness challenges to the specific dosing regimens and patient populations claimed.
  • For the composition of matter patent ('196), a central evidentiary question will be one of physical characterization: does the Defendants' proposed generic product, in fact, contain a polymorphic form of rifaximin that falls within the scope of the '196 patent's claims, an issue that will turn on expert chemical analysis and testing.
Loading Complaint